TY - JOUR
T1 - Somatostatin receptor ligands in acromegaly
T2 - clinical response and factors predicting resistance
AU - Paragliola, Rosa Maria
AU - Corsello, Salvatore Maria
AU - Salvatori, Roberto
N1 - Funding Information:
Rosa Maria Paragliola and Salvatore Maria Corsello have declares that they have no conflict of interest. Roberto Salvatori serves in advisory board for Pfizer, Novo Nordisk, and Ionis Pharmaceutical, receives research support from Novartis, Pfizer, and Chiasma, and has received in the past research support from Ipsen.
Publisher Copyright:
© 2016, Springer Science+Business Media New York.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Introduction: Somatostatin (SST) receptor ligands (SRL), in particular those of first generation (Octreotide and Lanreotide), are widely used in medical treatment of acromegaly, but they assure biochemical control of disease (and the possibility of an improvement of clinical symptoms and tumor shrinkage), only in a subset of patients. Discussion: The mechanisms underlying the so called “SRL resistance” are various and involve in particular SST receptor expression and molecular pathways of signal transduction. Different predictors of SRL response have been reported, including clinical and biochemical features (gender, age, growth hormone and insulin-like growth factor-I levels at diagnosis), and tumor characteristic (both at preoperative magnetic resonance imaging study and histopathology) as well as expression of SST receptors. In some cases, only a “partial resistance” to SST can be detected, probably due to the presence of other impaired molecular mechanisms involved in signal transduction, which compromise specific pathways and not others. This may explain some cases of dissociated response between biochemical control and tumor shrinkage.
AB - Introduction: Somatostatin (SST) receptor ligands (SRL), in particular those of first generation (Octreotide and Lanreotide), are widely used in medical treatment of acromegaly, but they assure biochemical control of disease (and the possibility of an improvement of clinical symptoms and tumor shrinkage), only in a subset of patients. Discussion: The mechanisms underlying the so called “SRL resistance” are various and involve in particular SST receptor expression and molecular pathways of signal transduction. Different predictors of SRL response have been reported, including clinical and biochemical features (gender, age, growth hormone and insulin-like growth factor-I levels at diagnosis), and tumor characteristic (both at preoperative magnetic resonance imaging study and histopathology) as well as expression of SST receptors. In some cases, only a “partial resistance” to SST can be detected, probably due to the presence of other impaired molecular mechanisms involved in signal transduction, which compromise specific pathways and not others. This may explain some cases of dissociated response between biochemical control and tumor shrinkage.
KW - Acromegaly
KW - Lanreotide
KW - Octreotide
KW - Pasireotide
KW - Resistance
KW - Somatostatin receptors ligands
UR - http://www.scopus.com/inward/record.url?scp=84992184293&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992184293&partnerID=8YFLogxK
U2 - 10.1007/s11102-016-0768-4
DO - 10.1007/s11102-016-0768-4
M3 - Review article
C2 - 27778296
AN - SCOPUS:84992184293
SN - 1386-341X
VL - 20
SP - 109
EP - 115
JO - Pituitary
JF - Pituitary
IS - 1
ER -